Recent Insider Transactions Derivative • 19h
Co-Founder notifies of intention to sell stock Xingjuan Chao intends to sell 39k shares in the next 90 days after lodging an Intent To Sell Form on the 8th of June. If the sale is conducted around the recent share price of US$18.36, it would amount to US$716k. For the year to December 2023, Xingjuan's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2025, Xingjuan's direct individual holding has increased from 682.19k shares to 1.03m. Company insiders have collectively bought US$16b more than they sold, via options and on-market transactions, in the last 12 months. Recent Insider Transactions Derivative • May 22
Co-Founder notifies of intention to sell stock Xingjuan Chao intends to sell 6k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of May. If the sale is conducted around the recent share price of US$18.00, it would amount to US$109k. For the year to December 2023, Xingjuan's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2025, Xingjuan's direct individual holding has increased from 685.07k shares to 1.05m. Company insiders have collectively sold US$6.4m more than they bought, via options and on-market transactions in the last 12 months. Major Estimate Revision • May 18
Consensus EPS estimates fall by 17% The consensus outlook for fiscal year 2026 has been updated. 2026 expected loss increased from -US$1.46 to -US$1.71 per share. Revenue forecast unchanged at US$114.0m. Medical Equipment industry in the US expected to see average net income growth of 13% next year. Consensus price target down from US$27.57 to US$26.86. Share price fell 19% to US$16.30 over the past week. Reported Earnings • May 12
First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2026 results: US$0.52 loss per share (further deteriorated from US$0.36 loss in 1Q 2025). Revenue: US$26.5m (up 29% from 1Q 2025). Net loss: US$19.7m (loss widened 55% from 1Q 2025). Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) missed analyst estimates by 33%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 8.0% growth forecast for the Medical Equipment industry in the US. Aankondiging • May 12
Ceribell, Inc. Raises Revenue Guidance for the Full Year 2026 CeriBell, Inc. raised revenue guidance for the full year 2026. For the year, the company is raising its revenue guidance for the full year 2026 to a range of $112 million to $116 million, representing growth of approximately 26% to 30% over the company’s prior year revenue. Recent Insider Transactions Derivative • May 04
Chief Technology Officer notifies of intention to sell stock Raymond Woo intends to sell 11k shares in the next 90 days after lodging an Intent To Sell Form on the 1st of May. If the sale is conducted around the recent share price of US$20.16, it would amount to US$224k. Since September 2025, Raymond's direct individual holding has decreased from 484.18k shares to 141.83k. Company insiders have collectively sold US$6.8m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Apr 07
Chief Technology Officer notifies of intention to sell stock Raymond Woo intends to sell 11k shares in the next 90 days after lodging an Intent To Sell Form on the 1st of April. If the sale is conducted around the recent share price of US$18.56, it would amount to US$206k. Since June 2025, Raymond's direct individual holding has increased from 464.87k shares to 483.39k. Company insiders have collectively sold US$6.4m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Mar 03
Chief Technology Officer notifies of intention to sell stock Raymond Woo intends to sell 11k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of March. If the sale is conducted around the recent share price of US$18.14, it would amount to US$202k. Since June 2025, Raymond's direct individual holding has increased from 464.87k shares to 484.10k. Company insiders have collectively sold US$5.8m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Feb 25
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: US$1.46 loss per share. Revenue: US$89.1m (up 36% from FY 2024). Net loss: US$53.4m (loss widened 32% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.0%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Medical Equipment industry in the US. Aankondiging • Feb 25
CeriBell, Inc. Provides Earnings Guidance for the Year 2026 CeriBell, Inc. provided earnings guidance for the year 2026. For the year, the company expects revenue for the full year 2026 to be in the range of $111 million to $115 million, representing growth of approximately 25% to 29% over the company’s prior year revenue. Recent Insider Transactions Derivative • Feb 20
Co-Founder notifies of intention to sell stock Josef Parvizi intends to sell 17k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of February. If the sale is conducted around the recent share price of US$20.27, it would amount to US$339k. Since June 2025, Josef's direct individual holding has decreased from 813.82k shares to 747.65k. Company insiders have collectively sold US$5.8m more than they bought, via options and on-market transactions in the last 12 months. Aankondiging • Feb 11
CeriBell, Inc. to Report Q4, 2025 Results on Feb 24, 2026 CeriBell, Inc. announced that they will report Q4, 2025 results After-Market on Feb 24, 2026 Recent Insider Transactions Derivative • Feb 03
Chief Technology Officer notifies of intention to sell stock Raymond Woo intends to sell 11k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of February. If the sale is conducted around the recent share price of US$20.80, it would amount to US$231k. Since June 2025, Raymond's direct individual holding has increased from 464.87k shares to 483.80k. Company insiders have collectively sold US$5.2m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Jan 16
Co-Founder notifies of intention to sell stock Josef Parvizi intends to sell 25k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of January. If the sale is conducted around the recent share price of US$22.94, it would amount to US$573k. Since June 2025, Josef's direct individual holding has decreased from 813.82k shares to 763.82k. Company insiders have collectively sold US$5.2m more than they bought, via options and on-market transactions in the last 12 months. Aankondiging • Jan 05
Ceribell, Inc. Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution Ceribell, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection monitor for patients in the hospital setting. This first-in-class LVO stroke detection monitor uses Ceribell's existing hardware and applies an AI-based algorithm to interpret EEG signals for early detection of LVO stroke. The Breakthrough Device Designation for LVO Stroke represents the latest achievement in Ceribell's continued efforts to extend its point-of-care EEG brain monitoring technology to additional indications, building on recent FDA 510(k) clearances for its next-generation Clarity®? algorithm to detect electrographic seizures in neonates (November 2025) and its proprietary delirium screening and monitoring solution (December 2025). Nearly 800,000 strokes occur annually in the U.S. In particular, LVO strokes are medical emergencies and have disproportionately higher morbidity and mortality compared to non-LVO ischemic stroke, contributing to 62% of post-stroke dependence and 96% of post-stroke mortality. Timely detection and access to treatment of LVO stroke can result in tremendous health benefits over patients' lifetimes, with every minute saved associated with a week of disability-free life. Unlike community-onset stroke, which occurs outside the hospital and often triggers immediate emergency response, in-hospital stroke affects patients who are already admitted. Scientific literature shows that stroke detection and treatment in hospitalized patients are often significantly delayed compared to strokes occurring outside of hospitals. This leads to worse outcomes, as patients face about three times higher rates of mortality, and are half as likely to be discharged home compared to community-onset stroke, even after adjusting for clinical characteristics and comorbidities in hospitalized patients. Out of 800,000 stroke patients, up to 17% are in-hospital-onset stroke. Dr. Chitra Venkatasubramanian, MBBS, MD, MSc, FNCS, Clinical Professor of Neurology and Neurosurgery, notes that: "In-hospital strokes frequently occur in units that aren't specialized in neurology, where bedside teams may not have sufficient training or tools to detect subtle neurological changes concerning a stroke. Recent Insider Transactions Derivative • Jan 04
Chief Technology Officer notifies of intention to sell stock Raymond Woo intends to sell 11k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of January. If the sale is conducted around the recent share price of US$21.89, it would amount to US$243k. Since June 2025, Raymond's direct individual holding has increased from 464.87k shares to 484.18k. Company insiders have collectively sold US$4.4m more than they bought, via options and on-market transactions in the last 12 months. Aankondiging • Jan 03
CeriBell, Inc. Announces Resignation of Lucian Iancovici as Chair of the Nominating and Corporate Governance Committee and as Member of the Compensation Committee, Effective as of December 31, 2025 On December 30, 2025, Lucian Iancovici notified the Board of Directors of CeriBell, Inc. of his resignation from the Board and from his positions as Chair of the Nominating and Corporate Governance Committee and as a member of the Compensation Committee, effective as of December 31, 2025. The resignation did not result from any disagreement with the Company on any matter relating to its operations, policies, or practices. Price Target Changed • Dec 11
Price target increased by 9.2% to US$27.00 Up from US$24.71, the current price target is an average from 7 analysts. New target price is 32% above last closing price of US$20.41. Stock is down 30% over the past year. The company is forecast to post a net loss per share of US$1.51 next year compared to a net loss per share of US$3.39 last year. Aankondiging • Dec 09
Ceribell, Inc. Receives FDA 510(k) Clearance for First-of-Its-Kind Delirium Monitoring Solution Ceribell, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its proprietary delirium monitoring solution, the first and only FDA cleared delirium screening and monitoring device. This clearance further establishes the Ceribell System as an AI-powered brain monitoring platform technology, extending the benefits to a larger population of critically ill patients and providing additional information to assist in diagnosing patients at risk for both seizures and delirium. Ceribell's delirium monitoring solution continuously analyzes EEG segments and notifies clinicians when patterns associated with delirium are detected, supporting more timely, reliable evaluation, and continuous monitoring of delirium. This validation underscores the algorithm's reliability and real-world utility for continuous delirium monitoring in the critical care setting. FDA clearance follows Ceribell's initial receipt of a Breakthrough Device Designation for delirium monitoring in 2022. Ceribell has submitted a New Technology Add-on Payment (NTAP) application to the Centers for Medicare and Medicaid Services (CMS) for this new indication. Delirium is a common and serious neurological condition affecting ~31% of ICU patients, and up to 80% of those who are mechanically ventilated. It is associated with poor clinical outcomes, including a 10% higher 6-month mortality risk for every day delirium is experienced, as well as longer hospital stays and increased hospitalization costs. The risk of post-ICU dementia is 60% higher in discharged ICU patients who have had delirium, compared to those who have not had delirium in the ICU. Current Society of Critical Care Medicine guidelines recommend regular delirium assessment using validated tools, underscoring the need for early and accurate detection. Recent Insider Transactions Derivative • Dec 03
Co-Founder notifies of intention to sell stock Xingjuan Chao intends to sell 25k shares in the next 90 days after lodging an Intent To Sell Form on the 1st of December. If the sale is conducted around the recent share price of US$16.87, it would amount to US$422k. For the year to December 2023, Xingjuan's total compensation was 27% salary and 73% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since December 2024, Xingjuan's direct individual holding has increased from 661.20k shares to 707.19k. Company insiders have collectively sold US$2.2m more than they bought, via options and on-market transactions in the last 12 months. Aankondiging • Nov 24
Ceribell, Inc. Receives Fda 510(K) Clearance for Use of Clarity Algorithm for Neonates Ceribell, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation Clarity algorithm to detect electrographic seizures in newborns pre-term and older. This clearance makes the Ceribell System the first and only AI-powered point-of-care electroencephalography (EEG) technology available to detect electrographic seizure in all ages of patients, from pre-term neonates through adults. Early detection of seizures represents a critical unmet need in neonatal care. While approximately 9% of neonatal intensive care unit (NICU) patients may be diagnosed with seizures,2,3 research suggests that up to 90% go undetected without EEG monitoring.4 As a result, a significant portion of NICU patients could benefit from expanded EEG screening. By combining proprietary algorithms with purpose-built hardware, the Ceribell System enables clinicians to detect non-convulsive seizures in neonatal patients in real time, supporting rapid diagnosis and treatment to help prevent serious brain injury. There is a clear need for faster, more accessible tools to evaluate brain activity at the bedside - especially in those critical first hours of life. Recent Insider Transactions Derivative • Nov 23
Co-Founder notifies of intention to sell stock Xingjuan Chao intends to sell 50k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of November. If the sale is conducted around the recent share price of US$15.13, it would amount to US$757k. For the year to December 2023, Xingjuan's total compensation was 27% salary and 73% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since December 2024, Xingjuan's direct individual holding has increased from 661.20k shares to 682.19k. Company insiders have collectively sold US$1.6m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Nov 14
Chief Technology Officer notifies of intention to sell stock Raymond Woo intends to sell 11k shares in the next 90 days after lodging an Intent To Sell Form on the 11th of November. If the sale is conducted around the recent share price of US$12.28, it would amount to US$136k. Since June 2025, Raymond's direct individual holding has increased from 464.87k shares to 484.18k. Company insiders have collectively sold US$1.5m more than they bought, via options and on-market transactions in the last 12 months. Price Target Changed • Nov 10
Price target decreased by 13% to US$24.71 Down from US$28.43, the current price target is an average from 7 analysts. New target price is 110% above last closing price of US$11.78. Stock is down 59% over the past year. The company is forecast to post a net loss per share of US$1.52 next year compared to a net loss per share of US$3.39 last year. Reported Earnings • Nov 06
Third quarter 2025 earnings: EPS and revenues exceed analyst expectations Third quarter 2025 results: US$0.37 loss per share. Revenue: US$22.6m (up 31% from 3Q 2024). Net loss: US$13.5m (loss widened 29% from 3Q 2024). Revenue exceeded analyst estimates by 3.7%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Aankondiging • Nov 05
CeriBell, Inc. Raising Earnings Guidance for the Full Year 2025 CeriBell, Inc. raised earnings guidance for the full year 2025. For the period, company expects revenue to a range of $87 million to $89 million, representing growth of approximately 33% to 36% over the company’s prior year revenue. Aankondiging • Oct 22
CeriBell, Inc. to Report Q3, 2025 Results on Nov 04, 2025 CeriBell, Inc. announced that they will report Q3, 2025 results After-Market on Nov 04, 2025 Price Target Changed • Oct 21
Price target decreased by 7.8% to US$28.43 Down from US$30.83, the current price target is an average from 7 analysts. New target price is 112% above last closing price of US$13.38. Stock is down 49% over the past year. The company is forecast to post a net loss per share of US$1.55 next year compared to a net loss per share of US$3.39 last year. Recent Insider Transactions Derivative • Oct 05
Chief Technology Officer notifies of intention to sell stock Raymond Woo intends to sell 11k shares in the next 90 days after lodging an Intent To Sell Form on the 3rd of October. If the sale is conducted around the recent share price of US$12.54, it would amount to US$139k. Since December 2024, Raymond's direct individual holding has increased from 117.70k shares to 484.18k. Company insiders have collectively sold US$1.5m more than they bought, via options and on-market transactions in the last 12 months. Aankondiging • Sep 23
Ceribell, Inc. Appoints Erica Rogers to the Board of Directors and Compensation Committee of the Board, Effective September 17, 2025 CeriBell, Inc. announced the appointment of Erica Rogers to its Board of Directors, effective September 17, 2025. Ms. Rogers brings over three decades of experience leading high-growth, innovative medical device companies to Ceribell’s Board as the Company executes on its mission to expand patient access to timely brain monitoring in the acute care setting. Ms. Rogers is an accomplished healthcare executive with board experience in both the public and private sectors. She most recently served as Chief Executive Officer of Silk Road Medical, Inc. and has held Board positions with HistoSonics, Axena Health, Sight Sciences, LightForce, and Medicines360. At Silk Road, Rogers led the business from its early stages through FDA approval and broad commercial expansion, which ultimately resulted in acquisition by Boston Scientific Corporation. Under her leadership, the organization grew significantly from a 25-person startup to a 500-employee, publicly-traded company with revenue exceeding $175 million. Emphasizing excellence and culture, she is a seasoned founder and leader with a proven track record of innovation, evident in multiple patents and successfully marketed products. Ms. Rogers has also been appointed to the Compensation Committee of the Board. Recent Insider Transactions Derivative • Sep 05
Chief Technology Officer notifies of intention to sell stock Raymond Woo intends to sell 11k shares in the next 90 days after lodging an Intent To Sell Form on the 4th of September. If the sale is conducted around the recent share price of US$12.11, it would amount to US$135k. Since December 2024, Raymond's direct individual holding has increased from 117.70k shares to 464.18k. Company insiders have collectively sold US$1.5m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions • Aug 24
Independent Director recently sold US$83k worth of stock On the 19th of August, Joseph Taylor sold around 7k shares on-market at roughly US$11.76 per share. This transaction amounted to 11% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Recent Insider Transactions Derivative • Aug 20
Independent Director notifies of intention to sell stock Joseph Taylor intends to sell 7k shares in the next 90 days after lodging an Intent To Sell Form on the 19th of August. If the sale is conducted around the recent share price of US$11.76, it would amount to US$83k. Since December 2024, Joseph's direct individual holding has increased from 44.21k shares to 57.44k. Company insiders have collectively sold US$1.4m more than they bought, via options and on-market transactions in the last 12 months. Aankondiging • Aug 06
Ceribell, Inc. Raises Its Revenue Guidance for the Full Year 2025 CeriBell, Inc. raised its revenue guidance for the full year 2025. For the year company expects revenue to a range of $85 million to $88 million, representing growth of approximately 30% to 34% over the company’s prior year revenue. Aankondiging • Jul 23
CeriBell, Inc. to Report Q2, 2025 Results on Aug 05, 2025 CeriBell, Inc. announced that they will report Q2, 2025 results After-Market on Aug 05, 2025 Recent Insider Transactions Derivative • Jul 08
Co-Founder notifies of intention to sell stock Xingjuan Chao intends to sell 25k shares in the next 90 days after lodging an Intent To Sell Form on the 7th of July. If the sale is conducted around the recent share price of US$18.80, it would amount to US$470k. For the year to December 2023, Xingjuan's total compensation was 27% salary and 73% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since December 2024, Xingjuan's direct individual holding has increased from 661.20k shares to 685.07k. Company insiders have collectively sold US$986k more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Jun 04
Co-Founder notifies of intention to sell stock Xingjuan Chao intends to sell 25k shares in the next 90 days after lodging an Intent To Sell Form on the 3rd of June. If the sale is conducted around the recent share price of US$17.15, it would amount to US$429k. For the year to December 2023, Xingjuan's total compensation was 27% salary and 73% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2024, Xingjuan's direct individual holding has increased from 227.00k shares to 685.07k. Company insiders have collectively sold US$347k more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • May 16
Co-Founder notifies of intention to sell stock Xingjuan Chao intends to sell 25k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of May. If the sale is conducted around the recent share price of US$16.59, it would amount to US$415k. For the year to December 2023, Xingjuan's total compensation was 27% salary and 73% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2024, Xingjuan's direct individual holding has increased from 227.00k shares to 636.20k. There has only been one transaction (US$2.3k purchase) from insiders over the last 12 months. Reported Earnings • May 10
First quarter 2025 earnings: EPS and revenues exceed analyst expectations First quarter 2025 results: US$0.36 loss per share. Revenue: US$20.5m (up 38% from 1Q 2024). Net loss: US$12.8m (loss widened 46% from 1Q 2024). Revenue exceeded analyst estimates by 6.2%. Earnings per share (EPS) also surpassed analyst estimates by 18%. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Aankondiging • May 09
Ceribell, Inc. Raises Revenue Guidance for Full Year 2025 CeriBell, Inc. raised revenue guidance for full year 2025. for the year, the company raised its revenue guidance for the full year 2025 to a range of $83 million to $87 million, representing growth of approximately 27% to 33% over the company’s prior year revenue. Board Change • May 04
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Independent Director Bill Burke was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Aankondiging • May 01
CeriBell, Inc., Annual General Meeting, Jun 10, 2025 CeriBell, Inc., Annual General Meeting, Jun 10, 2025. Aankondiging • Apr 30
Ceribell Receives FedRAMP High Authorization, Expanding Approval for Its AI-Powered Point-of-Care EEG Across Federal Healthcare Systems Ceribell, Inc. announced that its point-of-care electroencephalogram (EEG) system has received full FedRAMP®? (Federal Risk and Authorization Management Program) High authorization from the U.S. government. This elite security authorization is awarded to organizations that meet the government's higher security requirements. Ceribell's secure, cloud-based solution can now be adopted across federal healthcare systems, expanding access to rapid diagnosis of non-convulsive seizures for U.S. veterans and other high-risk patients. As of April 28, 2025, only 51 companies in the U.S. have achieved High authorization, and there are no other medical device companies on that list. Designed for rapid setup and continuous brain monitoring, the Ceribell system is already in use at hospitals within the Department of Veterans Affairs (VA) after receiving Authority to Operate (ATO) in 2024. Now, FedRAMP High authorization paves the way for broader implementation throughout federal healthcare agencies, including the entire VA system, enabling more efficient deployment and secure data sharing between facilities. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: risks related to the macroeconomic and geopolitical environment and the potential imposition of new or higher threats; risks related to limited operating history and history of net losses; ability to successfully achieve substantial market acceptance and adoption of products; competitive pressures; ability to adapt manufacturing and production capacities to evolving patterns of demand, governmental actions and customer trends; the manufacturing of a substantial number of product components and their assembly in China; product defects or complaints and related liability; the complexity, timing, expense, and outcomes of clinical studies; ability to obtain and maintain adequate coverage and reimbursement levels for its products; ability to comply with changing laws and regulatory requirements and resulting costs; dependence on a limited number of suppliers; and other risks and uncertainties, including those described under the heading "Risk Factors" in annual Report on Form 10-K and other reports filed with the U.S. Securities and Exchange Commission ("SEC"). Aankondiging • Apr 25
CeriBell, Inc. to Report Q1, 2025 Results on May 08, 2025 CeriBell, Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025 Recent Insider Transactions Derivative • Apr 20
Co-Founder notifies of intention to sell stock Xingjuan Chao intends to sell 6k shares in the next 90 days after lodging an Intent To Sell Form on the 17th of April. If the sale is conducted around the recent share price of US$15.02, it would amount to US$86k. For the year to December 2023, Xingjuan's total compensation was 20% salary and 80% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2024, Xingjuan's direct individual holding has increased from 227.00k shares to 661.20k. There has only been one transaction (US$2.3k purchase) from insiders over the last 12 months. New Risk • Apr 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$31m net loss in 3 years). Share price has been volatile over the past 3 months (15% average weekly change). Major Estimate Revision • Mar 04
Consensus EPS estimates fall by 44%, revenue upgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from US$81.3m to US$83.7m. Forecast EPS reduced from -US$1.17 to -US$1.69 per share. Medical Equipment industry in the US expected to see average net income growth of 19% next year. Consensus price target of US$33.25 unchanged from last update. Share price fell 7.0% to US$23.76 over the past week. Reported Earnings • Feb 26
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2024 results: US$3.39 loss per share. Revenue: US$65.4m (up 45% from FY 2023). Net loss: US$40.5m (loss widened 37% from FY 2023). Revenue exceeded analyst estimates by 1.7%. Earnings per share (EPS) missed analyst estimates by 54%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Aankondiging • Feb 26
Ceribell, Inc. Provides Revenue Guidance for the Full Year 2025 CeriBell, Inc. provided revenue guidance for the full year 2025. For the year, the company expects revenue to be in the range of $81 million to $85 million, representing growth of approximately 24% to 30% over the company’s prior year revenue. Seeking Alpha • Feb 21
CeriBell: A Leader In AI-Powered Seizure Detection Summary
AI is revolutionizing clinical diagnostics, achieving high accuracy and speed in detecting diseases like Crohn's, fatty liver, coronary artery disease, sepsis, and cancer.
CeriBell's AI-powered EEG system offers rapid seizure diagnosis, significantly reducing setup time and ICU stays, thus lowering patient morbidity, mortality, and healthcare costs.
Clarity Pro algorithm, FDA-approved in 2023, enhances non-convulsive seizure diagnosis, enabling faster response by ancillary healthcare workers and improving clinical outcomes.
CeriBell's commercial scaling, strong management, and recent financial trends indicate robust growth potential, supported by a favorable valuation analysis and upcoming catalysts.
I consider the stock undervalued by at least 50% over the long term. Upcoming February 25 earnings are a catalyst.
Read the full article on Seeking Alpha Aankondiging • Feb 12
CeriBell, Inc. to Report Q4, 2024 Results on Feb 25, 2025 CeriBell, Inc. announced that they will report Q4, 2024 results After-Market on Feb 25, 2025 Aankondiging • Nov 20
CeriBell, Inc. Appoints Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing CeriBell, Inc. announced the appointments of Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing to its leadership team. Kristie Rodenbush, Chief People Officer: Ms. Rodenbush will oversee Ceribell’s People & Culture team. She has more than 25 years of human resources and talent management experience which spans various industries and includes roles at companies ranging from startups to publicly traded, international organizations. Most recently, she served as Chief People Officer of Meltwater, where she led human resources functions for more than 2,400 employees located in 30 countries. Ms. Rodenbush holds a Bachelor of Arts in Psychology from the University of California, San Diego. Brian Price, Senior Vice President of Marketing: Mr. Price is an industry veteran who brings to Ceribell more than 25 years of experience in the medical device industry, including marketing leadership roles at Medtronic and Abbott. In his new role at Ceribell, he will leverage his expertise in market development, product portfolio planning, business development, health economics, reimbursement and sales. He most recently served as Chief Marketing Officer of VitalConnect, and previously held sales and marketing leadership roles with LivaNova, St. Jude Medical, WebMD and Guidant Corporation, where he drove multiple incremental product launches and disruptive therapy platforms across many specialties including neurology, cardiology, urology and gynecology. Mr. Price holds a Master of Business Administration degree from the University of Minnesota Carlson School of Management and a Bachelor of Science in Organizational Leadership and Industrial Technology from Purdue University. Aankondiging • Nov 13
CeriBell, Inc. Provides Revenue Guidance for the Year 2024 CeriBell, Inc. provided revenue guidance for the year 2024. The company expects revenue for the full year 2024 to be in the range of $64.2 million to $64.7 million, representing growth of 42% to 43% over the company’s prior year revenue. Aankondiging • Nov 12
Ceribell Receives Authority to Operate from the U.S. Department of Veterans Affairs CeriBell, Inc. announced the receipt of an Authority to Operate (ATO) from the Department of Veterans Affairs (VA). The ATO is a significant milestone in achieving authorization within the framework of federal government cloud computing security requirements and it allows Veterans Administration (VA) hospitals to fully deploy Ceribell’s point-of-care EEG technology. While Ceribell has been used in certain VA facilities since 2018, this ATO allows Ceribell to leverage VA Wi-Fi networks, enabling remote access to EEG reports and sharing of EEG data between VA locations. Broader use of Ceribell’s features will enable VA hospitals to more efficiently manage neurological emergencies by supporting timely interventions and improved patient outcomes.1-3 The Ceribell System has the potential to provide continuity of care and reduce costs by helping to avoid the transfer of patients to other facilities. Aankondiging • Oct 30
CeriBell, Inc. to Report Q3, 2024 Results on Nov 12, 2024 CeriBell, Inc. announced that they will report Q3, 2024 results at 4:00 PM, US Eastern Standard Time on Nov 12, 2024